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Phosphatase and tensin homologue (PTEN), one of thewell-characterized tumor suppressor proteins, counteracts the
phosphatidylinositol 3-kinase-AKT pathway through its unique lipid phosphatase activity. The functions of PTEN are
regulated by a variety of posttranslationalmodifications such as acetylation, oxidation, ubiquitylation, phosphorylation,
andSUMOylation. However,methylation of PTENhas not been reported so far. In this study,wedemonstrated that the
oncogenic protein lysine methyltransferase SET and MYND domain containing 2 (SMYD2) methylates PTEN at lysine
313 in vitro and in vivo. Knockdown of SMYD2 suppressed the cell growth of breast cancer cells and attenuated
phosphorylation levels of AKT, indicating that SMYD2-mediated methylation negatively regulates PTEN tumor
suppressor activity and results in activation of the phosphatidylinositol 3-kinase-AKT pathway. Furthermore, PTEN
protein with lysine 313 substitution diminished phosphorylation of PTEN at serine 380, which is known to inactivate
tumor suppressor functions of PTEN. Taken together, our findings unveil a novel mechanism of PTEN dysregulation
regulated by lysine methylation in human cancer.
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Phosphatase and tensin homologue (PTEN) was originally identified to
be frequently disrupted inmultiple sporadic tumor types and targeted by
germline mutations in patients with cancer predisposition syndromes
like Cowden disease [1,2]. Subsequently, the generation of Pten
knockout mice demonstrated the important tumor suppressor functions
of PTEN in various types of cancer [3–5]. PTEN has lipid phosphatase
activity, which converts phosphatidylinositol-3,4,5-triphosphate to
phosphatidylinositol-4,5-biphosphate and antagonize the AKT signaling
pathway [6]. The AKT signaling pathway is involved in multiple
physiological processes including cell survival and proliferation and
cellular metabolism. Dysregulation of AKT activity often causes a variety
of diseases, including cancer [7]. Hence, this phosphatidylinositol-3,4,5-
triphosphate lipid phosphatase activity of PTEN is widely recognized as
an important tumor-suppressor function. PTEN consists of a
phosphatidylinositol 4,5-biphosphate binding domain, a phosphatase
domain, a C2 domain, a carboxy-terminal tail, and a PDZ-binding
domain [8]. While the N-terminal portion containing the phos-
phatidylinositol 4,5-biphosphate binding domain and phosphatase
domain is a catalytic core for phosphatase activity, the C2 domain is
critical to recruit PTEN to the membrane, where PTENworks as a lipidphosphatase [8]. It is well known that the PTEN functions are regulated
by a variety of posttranslational modifications such as acetylation,
oxidation, ubiquitylation, phosphorylation, and SUMOylation. For
instance, acetylation of lysines 125 and 128 within the catalytic pocket
that are mediated by p300/CBP-associated factor in response to the
growth factor stimulation negatively regulates the tumor suppressor
activity of PTEN [9]. Reactive oxygen species–mediated linkage of
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inactivates PTEN [10]. In addition, the E3 ligase neural precursor cell
expressed developmentally down-regulated protein 4 monoubiquitylates
and polyubiquitylates PTEN; polyubiquitylation promotes rapid
degradation, whereas monoubiquitylation is important for PTEN
nuclear translocation [11,12]. Furthermore, multiple kinases have
been reported to phosphorylate PTEN and regulate protein stability
and function of PTEN [13–16]. However, methylation of PTEN has
not been reported. In the present study, we describe that SET and
MYND domain containing 2 (SMYD2), a protein lysine methyltrans-
ferase that is known to be involved in human tumorigenesis, methylates
PTEN at lysine 313 in vitro and also in vivo. Our results imply that
SMYD2-mediated methylation attenuates the tumor suppressor activity
of PTENas a regulator of the phosphatidylinositol 3-kinase (PI3K)-AKT
signaling pathway, which results in the promotion of cancer cell growth.
Methods
Antibodies
The following primary antibodies were used: anti-FLAG (mouse,M2;
Sigma-Aldrich, St Louis, MO; dilution used in immunocytochemistry:
1:2000), anti-human influenza hemagglutinin (rabbit, Y-11; Santa Cruz
Biotechnology, Dallas, TX; dilution used in Western blotting: 1:3000,
ICC: 1:1000), anti-SMYD2 (rabbit, D14H7; Cell Signaling Technol-
ogy, Danvers, MA; dilution used in WB: 1:1000), anti-phosphorylated
AKT (Thr 308) (rabbit, D25E6; Cell Signaling Technology; dilution
used in WB: 1:1000), anti-AKT (rabbit, C67E7; Cell Signaling
Technology; dilution used in WB: 1:1000), anti–α-tubulin (mouse,
DM1A; Calbiochem, Billerica, MA; dilution used in WB: 1:1000), and
anti–phospho-PTEN (Ser 380) (rabbit, Cell Signaling Technology,
dilution used in WB: 1:1000). An anti-K313 dimethylated PTEN
antibody (Sigma-Aldrich; dilution used in WB: 1:1000) was produced
in rabbit immunized with a synthetic peptide.
Cell Culture
HeLa, HEK293T, and MDA-MB-231 cell lines were obtained from
AmericanTypeCultureCollection (ATCC) (Manassas, VA). All cell lines
were grown inmonolayers in appropriate media supplemented with 10%
FBS and 1%antibiotic/antimycotic solution (Sigma-Aldrich):Dulbecco’s
modified Eagle’s medium for HEK293T cells; Eagle’s minimal essential
medium forHeLa cells; Leibovitz’s L-15 forMDA-MB-231 cells. All cells
were maintained at 37°C in humid air with 5% CO2 condition
(HEK293T and HeLa) or without CO2 (MDA-MB-231). Cells were
transfected with FuGENE6 or Fugene HD (Promega, Fitchburg, WI)
according to the manufacturer’s protocols [17,18].
In Vitro Methyltransferase Assay
In vitro methyltransferase assays were described previously [17,19–22].
Briefly, recombinant PTEN protein was incubated with recombinant
SMYD2 and 2 μCi S-adenosyl-L-[methyl-3H]-methionine (PerkinElmer,
Waltham,MA) in amixture ofmethylase activity buffer (50mMTris-HCl
at pH 8.8, 10 mM DTT, and 10 mMMgCl2) for 1 hour at 30°C. After
denaturing, samples were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE), blotted to polyviny-
lidene difluoride membrane, and visualized by MemCode Reversible
Stain (Thermo Fisher Scientific, Waltham, MA) and fluorography.
Mass Spectrometry
The reaction mixture of in vitro methyltransferase assay was
analyzed by nano liquid chromatography–tandem mass spectrometry(LC-MS/MS) using Q Exactive Hybrid Quadrupole-Orbitrap Mass
Spectrometer (Thermo Fisher Scientific GmbH, Bremen, Germany).
The peptides were separated using nano ESI spray column (NTCC
analytical column, C18, 75 µm[ID] × 100 mm[L], 3µm, Nikkyo
Technos Co., Ltd.) at a flow rate of 300 nl/min. The mass spectrometer
was operated in the positive-ion mode, and the spectra were acquired in
a data-dependent top 10 MS/MS mode. The MS/MS spectra were
searched against the in-house database using local MASCOT server
(version 2.2.1; Matrix Sciences, London, United Kingdom). The
reaction mixture was desalted and applied to matrix-assisted laser
desorption/ionization - time of flight - mass spectrometry using an
ultrafleXtreme (Bruker Daltonik GmbH, Bremen, Germany).
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde in 0.1 M phosphate
buffer at 4°C for 1 hour, permeabilized in 0.1% Triton X-100
(Sigma-Aldrich) for 3 minutes at room temperature, and blocked with
3% BSA for 1 hour at room temperature. Fixed cells were incubated
with each primary antibody overnight at 4°C followed by incubation
with Alexa Fluor–conjugated secondary antibody (Life Technologies,
Carlsbad, CA) [23,24] and observed using Leica confocal microscopy
(SP5 Tandem Scanner Spectral 2-Photon Confocal).
Western Blot Analysis
Samples were prepared from the cells lysed with CelLytic M lysis
reagent (Sigma-Aldrich) supplemented with complete protease
inhibitor cocktail (Roche Applied Science, Penzberg, Germany).
Whole-cell lysates or immunoprecipitated samples were separated by
SDS-PAGE and blotted to nitrocellulose membrane. Protein bands
were detected by incubating with HRP-conjugated antibodies (GE
Healthcare, Little Chalfont, United Kingdom) and visualizing with
enhanced chemiluminescence (GE Healthcare).
Small Interfering RNA Transfection
Small interfering RNA (siRNA) oligonucleotide duplexes were
purchased from Sigma-Aldrich for targeting SMYD2 transcripts.
siEnhanced green fluorescent protein and siNegative control (siNC),
which is a mixture of three different oligonucleotide duplexes, were used
as control siRNAs [25–28]. The siRNA sequences are described in Table
W1. siRNA duplexes were transfected with Lipofectamine RNAi max
(Life Technologies). Cell viability was examined by Cell Counting Kit-8
(Dojindo, Kumamoto, Japan).
Cell Cycle Analysis by Flow Cytometry
A 5′-bromo-2′-deoxyuridine (BrdU) flow kit (BD Biosciences,
Franklin Lakes, NJ) was used to determine the cell cycle kinetics and
to measure the incorporation of BrdU into DNA of proliferating cells
[25]. The assay was performed according to the manufacturer’s
protocol. Briefly, cells (5 × 105 per dish) were seeded overnight in
10-cm diameter tissue culture dishes and treated with an optimized
concentration of siRNAs for 96 hours, followed by addition of 10 μM
BrdU, and incubations continued for an additional 35 minutes.
Floating and adherent cells were pooled from triplicate wells per
treatment point, fixed in a solution containing paraformaldehyde
and saponin, and incubated for 1 hour with DNAase at 37°C (30 μg
per sample). Fluorescein isothiocyanate–conjugated anti-BrdU
antibody (1:50 dilution in wash buffer; BD Pharmingen, San
Diego, CA) was added and incubated for 20 minutes at room
temperature. Cells were washed in wash buffer and total DNA was
stained with 7-amino-actinomycin D (7-AAD; 20 μl per sample),
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Figure 1. SMYD2 methylates PTEN at lysine 313 in vitro. (A) Recombinant PTEN protein was methylated by SMYD2 in a dose-dependent
manner.MethylatedPTENwasdetectedby fluorography, and lodgingproteinswere visualizedbyMemCodeReversible Protein stain. (B) LC-MS/
MS spectrum of the dimethylated PTEN 309-322 peptide. PTEN recombinant protein was reacted with SMYD2 followed by SDS-PAGE. LC-MS/
MS analysis was conducted after digestion of samples by trypsin. (C) Wild-type PTEN (PTEN-WT) and mutant-type PTEN (N311A and K313A)
were prepared andused for an in vitromethyltransferase assay.Methylation signal of PTENwasdiminishedwhen lysine 313was substituted. (D)
Methylation site is displayed in the crystal structure of PTEN (PDB ID:1D5R). Lysine 313 is located in the large flexible internal loop, and the lysine
residue is evolutionally conserved.
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Total DNA content (7-AAD) was determined by FlowJo software.
Results
In Vitro Methylation of PTEN by SMYD2
To clarify whether PTEN can bemethylated, we conducted an in vitro
methyltransferase assay using multiple recombinant histone lysine or
arginine methyltransferases (Figure W1) and found that SMYD2
methylated PTEN in a dose-dependent manner (Figures 1A and W2).
Subsequently, we conducted LC-MS/MS analysis and identified that
lysine 313 of PTEN is dimethylated by SMYD2 (Figures 1B and W3).
To further verify the SMYD2-mediated PTENmethylation at this lysine
residue, we prepared wild-type and lysine 313–substituted recombinant
PTEN proteins and performed an in vitro methyltransferase assay and
confirmed that the PTENmethylation signal was significantly attenuated
when we used the lysine 313–substituted PTEN as a substrate
(Figure 1C). These results indicate that SMYD2 methylates PTEN at
lysine 313 in vitro. This lysine residue is located in a highly flexible
internal loop in theC2 domain of PTEN [8] and highly conserved among
species (Figure 1D).In Vivo PTEN Methylation
We subsequently performed immunocytochemical analysis and
confirmed co-localization of SMYD2 and PTEN in the cytoplasm
(Figure 2A). To verify the in vivo methylation, we generated a
polyclonal antibody that specifically recognizes PTEN with dimethy-
lation at lysine 313 (PTENK313me2). The specificity of the antibody
was confirmed by ELISA, which shows high affinity only to the
methylated PTEN peptide (Figure W4). Then, we transfected FLAG-
Mock and FLAG-SMYD2 into HEK293T cells and performed
immunoprecipitation to analyze the methylation status of endoge-
nous PTEN protein using the methylation-specific antibody. As
shown in Figure 2B, the PTEN methylation signal was significantly
higher in FLAG-SMYD2-transfected cells than FLAG-Mock-trans-
fected cells. In addition, we also examined the methylation level of
PTEN after knockdown of SMYD2 in the breast cancer MDA-
MB-231 cells and confirmed that the methylation signal was
decreased by knockdown of SMYD2 (Figure 2, C and D), indicating
that SMYD2 methylates PTEN in cancer cells. Furthermore, we
co-transfected FLAG-SMYD2 and HA-tagged wild-type PTEN (HA-
PTEN-WT) or K313A mutant–type PTEN (HA-PTEN-K313A)
into HEK293T cells and immunoprecipitated HA-PTEN proteins
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Figure 2. PTEN is methylated in vivo. (A) PTEN and SMYD2 were co-localized in the cytoplasm. HeLa cells were stained with anti-FLAG (for
FLAG-tagged PTEN; Alexa Fluor 594, red) and anti-HA (for HA-tagged SMYD2; Alexa Fluor 488, green) antibodies and 4',6-diamidino-2-
phenylindole (blue). Bar, 20 μm. (B) The endogenous PTEN methylation level was examined after SMYD2 overexpression. FLAG-Mock and
FLAG-SMYD2 were transfected into HEK293T cells, and immunoprecipitation using anti-PTEN antibody was conducted 48 hours after
transfection. SMYD2 overexpression clearly increased PTENmethylation. (C) Themethylation level of endogenous PTENwas examined after
SMYD2 knockdown.MDA-MB-231 cells were treatedwith control siRNA or siSMYD2, and immunoprecipitation using an anti-PTEN antibody
was conducted 96 hours after transfection. PTENmethylationwas attenuated bySMYD2knockdown. (D) Relativemethylation levels of PTEN
after SMYD2 knockdown. Signal intensity of the bands corresponding to K313methylation of PTENwas quantified using a GS-800 calibrated
densitometer (Bio-Rad, Hercules, CA). (E) Wild-type or lysine 313–substituted PTEN was overexpressed in HEK293T cells, and whole-cell
lysate (input) and immunoprecipitated fractions were subjected to Western blot analysis using the anti-dimethylated K313 PTEN antibody
(PTENK313me2). An anti-HA antibody was used as an internal control. Methylation signal was abolished in PTEN-K313A proteins.
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anti-PTEN K313me2 antibody. Consequently, we observed
attenuationx of the methylation-specific signal in the lysine 313–
substituted PTEN protein (Figure 2E). Taken together, these results
strongly reveal that PTEN is methylated at lysine 313 both in vitro
and in vivo by SMYD2.
Negative Regulation of the Tumor Suppressor Activity of PTEN
through SMYD2-Mediated Methylation
To address the biologic significance of the PTEN methylation in
cancer cells, we examined the cell growth of breast cancer cells that
overexpress SMYD2 by knockdown of SMYD2 (Figure 3A) [29].
The growth of two breast cell lines, MDA-MB-231 and MCF7 thatexpress wild-type PTEN [30,31], was significantly suppressed by
treatment with two different SMYD2 siRNAs (Figure 3A). To further
assess the mechanism of growth suppression caused by SMYD2
knockdown, we performed BrdU and 7-AAD staining and examined
cell cycle status (Figure W5). The proportion of MDA-MB-231 cells
at the G1 phase was significantly increased after treatment with
siSMYD2, while that at the S phase was remarkably decreased
(Figure W5). This result has implied that SMYD2 is likely to play an
important role in the G1/S transition of cancer cells. Since it is well
known that PTEN negatively regulates the G1/S transition [32],
SMYD2-mediated methylation might affect this PTEN function.
Given that PTEN is known to counteract the activation of the PI3K-
AKT pathway [33], we examined the phosphorylation status of AKT
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Figure 3. SMYD2-mediated methylation regulates the tumor suppressor activity of PTEN. (A) Cell growth assays of MDA-MB-231 and
MCF7 cells after treatment with siNC (control), siEnhanced green fluorescent protein (control), siSMYD2#1, or siSMYD2#2. Knockdown
of SMYD2 suppressed the cancer cell growth. Relative cell numbers are normalized to the number of siNC-treated cells (siNC = 1).
Results are the mean of six independent experiments, and P values were calculated with Student’s t test (*P b .001). (B) Phosphorylation
levels of AKT in MDA-MB-231 cells were examined by Western blot analysis 96 hours after treatment with siRNAs. SMYD2 knockdown
resulted in the attenuation of phosphorylation levels of AKT. (C) Wild-type PTEN and K313A mutant–type PTEN were overexpressed in
HEK293T cells and phosphorylation levels of the proteins were examined 48 hours after transfection. The phosphorylation level of serine
380 on PTENwas diminished in K313-substituted PTEN. (D) Signal intensity of phosphor-PTEN (Ser 380) was quantified and normalized by
PTEN amount using a GS-800 calibrated densitometer (Bio-Rad). (E) Wild-type PTEN was co-transfected with FLAG-Mock or FLAG-
SMYD2 into HEK293T cells. Cells were harvested 48 hours after transfection followed by immunoprecipitation using anti-HA agarose
beads. Samples were immunoblotted with anti-FLAG, anti-tubulin, alpha 1a, anti-HA, and anti–phospho-PTEN (Ser 380) antibodies.
(F) Signal intensity phospho-PTEN (Ser 380) was quantified and normalized by PTEN amount.
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levels of AKT were significantly decreased after SMYD2 knockdown.
Then, we hypothesized that this attenuation of AKT after SMYD2
knockdown may be caused by the increase of PTEN activity. It was
reported that phosphorylation of PTEN represses its tumor
suppressor functions [1]. We and others reported that lysine
methylation can affect the phosphorylation status of another amino
acid in the same protein [34]. Therefore, we examined the relationship
between lysine 313 methylation and the phosphorylation status of
PTEN. As shown in Figure 3, C and D, methylation-inactive PTEN
(PTEN-K313A) shows significantly lower phosphorylation levels (Ser
380) than wild-type PTEN. Furthermore, we examined phosphorylation
levels of PTEN in the presence or absence of SMYD2 overexpression.
The results clearly confirmed that the phosphorylation level of PTENwas
significantly increased by co-overexpression of SMYD2 (Figure 3, E and
F). This phosphorylation was reported to be involved in inactivation ofPTEN tumor suppressor functions by promoting “closed conformation”
of PTEN and resulting in dissociation of the C2 domain from the
membrane [15,35]. In summary, these results suggest a model that
SMYD2-mediatedmethylation of PTENat lysine 313 diminishes PTEN
tumor suppressor activity through enhancement of phosphorylation at
serine 380 (Figure 4).
Discussion
Here, we have demonstrated that SMYD2 methylates PTEN at lysine
313 both in vitro and in vivo. Our findings suggest that the SMYD2-
mediated PTEN methylation negatively regulates the tumor
suppressor activity of PTEN on the PI3K-AKT signaling pathway
and promotes cancer cell proliferation. Given a critical role of PTEN
as a tumor suppressor and that the PI3K-AKT signaling pathway is
one of the key signaling pathways in human cancer, the attenuation
of PTEN tumor suppressor functions by SMYD2-mediated
C-tail
Phosphatase C2
SMYD2
Suppression of AKT activity
PTEN
Phosphatase C2
P P P
Me
PTEN
AKT
AKT
P P
Inactivation of PTEN function
Activation of AKT activity
Promote tumorigenesis
Figure 4.Model of the SMYD2-mediated PTEN methylation function. Methylation promotes phosphorylation of the C-tail of PTEN, which
may induce inactive conformation.
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Genetic alteration of PTEN, including somatic mutations and
deletion, and/or epigenetic silencing are frequently observed in
various types of cancer [36]. In addition to these known mechanisms of
PTEN dysregulation, we unveil a novel mechanism of PTEN
suppression mediated by lysine methylation through SMYD2.
Importantly, the data set from cBioPortal for Cancer Genomics
indicates that the amplification of SMYD2 and alteration of the PTEN
gene would be mutually exclusive in breast cancer (FigureW6) [37,38].
It may also support our hypothesis that the lysine methylation would be
one of the mechanisms of PTEN functional loss.
Although SMYD2 was originally identified as a histone methyl-
transferase that specifically methylates H3K36 [39], recent studies
identified various non-histone protein substrates of SMYD2 such as
p53, retinoblastoma 1, heat shock protein 90kDa, estrogen receptor
alpha, and poly (ADP-ribose) polymerase 1 [21,40–43]. Our present
and previous studies demonstrated that SMYD2 is mainly localized in
the cytoplasm (Figure 2A) [21,29,42], implying that the functionally
important substrates of SMYD2 in human tumorigenesis may not be
histone proteins but non-histone cytoplasmic proteins. To date, how
SMYD2 specifically recognizes its substrates remains largely unknown.
Recent structural and biochemical analyses suggested some consensus
sequences for other methyltransferases, SET7/9 and SUV39H2
[44,45], but any consensus sequence has not been indicated for
SMYD2. Additional in vitro studiesmay explore the substrate specificity
of SMYD2.
Our study indicates that SMYD2-mediated PTEN methylation at
lysine 313 promotes phosphorylation at serine 380 of PTEN. In this
case, the methylation site is not adjacent to the phosphorylation site.
However, since these lysine and serine residues are located in a highly
flexible internal loop or loosely folded C-terminal region [8], they
may stay close to each other in the tertiary structure. Although the
detailed molecular mechanism by which methylation modulates
phosphorylation still remains to be elucidated, it may affect theinteraction between PTEN and CK2, which phosphorylates serine
380 [15]. Cross-talk of various types of posttranslational modifica-
tions on histone proteins as well as non-histone proteins, including
methylation, is widely recognized [29,40,41,46–48].
In conclusion, we identified PTEN as a novel substrate of SMYD2. The
SMYD2-mediated methylation negatively regulates the PTEN tumor-
suppressive function on the PI3K-AKT pathway through inducing PTEN
phosphorylation, which enhances the cancer cell growth. Given that it is
frequently overexpressed in various types of cancer [29], SMYD2 is likely to
be a promising target for development of novel anti-cancer therapy.
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